THERAPEUTIC SEGMENT:
Aromatase Inhibitors

INDICATIONS:
Sciletro is indicated for:

• Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
• Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy.
• First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer

BRIEF DESCRIPTION:
Letrozole is a nonsteroidal competitive inhibitor of the aromatase enzyme system; it inhibits the conversion of androgens to estrogens.

DOSAGE FORM:
Tablets
2.5mg

Disclaimer: For use under medical prescription only